首页> 外文期刊>Nature Communications >CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
【24h】

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil

机译:CETSA筛选可识别已知和新颖的胸苷酸合酶抑制剂和5-氟尿嘧啶的细胞内激活缓慢

获取原文
获取外文期刊封面目录资料

摘要

Target engagement is a critical factor for therapeutic efficacy. Assessment of compound binding to native target proteins in live cells is therefore highly desirable in all stages of drug discovery. We report here the first compound library screen based on biophysical measurements of intracellular target binding, exemplified by human thymidylate synthase (TS). The screen selected accurately for all the tested known drugs acting on TS. We also identified TS inhibitors with novel chemistry and marketed drugs that were not previously known to target TS, including the DNA methyltransferase inhibitor decitabine. By following the cellular uptake and enzymatic conversion of known drugs we correlated the appearance of active metabolites over time with intracellular target engagement. These data distinguished a much slower activation of 5-fluorouracil when compared with nucleoside-based drugs. The approach establishes efficient means to associate drug uptake and activation with target binding during drug discovery.
机译:靶标参与是治疗功效的关键因素。因此,在药物开发的所有阶段中,非常需要评估化合物与活细胞中天然靶蛋白的结合。我们在此报告基于细胞内靶标结合的生物物理测量结果的第一个化合物文库筛选,以人胸苷酸合酶(TS)为例。屏幕为所有测试过的已知作用于TS的药物准确选择了筛选。我们还鉴定了具有新颖化学作用的TS抑制剂和市售药物,这些药物以前都不是靶向TS的,包括DNA甲基转移酶抑制剂地西他滨。通过跟踪已知药物的细胞吸收和酶促转化,我们将活性代谢物随时间的出现与细胞内靶标结合相关联。与基于核苷的药物相比,这些数据表明5-氟尿嘧啶的活化慢得多。该方法建立了在药物发现过程中将药物吸收和激活与靶标结合相关联的有效手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号